Ironwood Pharmaceuticals Investigated for Potential Violations of Federal Securities Laws by Block & Leviton LLP

BOSTON, April 26, 2016 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Ironwood Pharmaceuticals (NASDAQ: IRWD) and certain of its officers and directors have violated federal securities laws following the publication today by Phase Five Research of a report entitled "Uncovered: fatal safety issues linked with Ironwood's drug, Linzess".

Ironwood shares were trading down over 10% in early trading on Tuesday following the publication of the report. Among other things, the report alleges that "Contrary to IRWD's claims, Linzess's side effects are not limited to the gastrointestinal (GI) tract," but are instead causing "previously unknown, unreported and unlabeled severe systemic adverse events, including documented cases of rapid weight gain, renal failure, seizures and strokes."

If you have purchased or otherwise acquired IRWD securities on or before April 25, 2016, and have questions about your legal rights or possess information relevant to this investigation, please contact attorney Jake Walker at (617)398-5600 or by email at [email protected]. Confidentiality to whistleblowers or others with information relevant to the lawsuit is assured.

Block & Leviton LLP is a Boston-based law firm representing investors nationwide. The firm's lawyers have collectively been prosecuting securities cases on behalf of individual and institutional investors for over 70 years, and have recovered billions of dollars on their behalf. Block & Leviton's investigations into corporate wrongdoing were recently covered by the New York Times.

This notice may constitute attorney advertising.

CONTACT:
Block & Leviton LLP
Jacob Walker
155 Federal Street, Suite 400
Boston, MA 02110
(617)398-5600
[email protected]

SOURCE Block & Leviton LLP

Related Links

http://www.blockesq.com